Bharat Biotech will have to submit the safety and efficacy data from the ongoing phase 3 clinical trial in the country.
source https://www.hindustantimes.com/india-news/covid-19-vaccine-data-india-seeks-from-serum-institute-bharat-biotech-canada-s-approval-to-pfizer-10-points/story-cXqiVKhG8XcHSmMcCCswtI.html
No comments:
Post a Comment